Why the study?
PVI efficacy remains suboptimal in persistent AF, and while targeting low voltage areas (LVAs) has been proposed, randomized trial results are mixed and significant heterogeneity exists in identifying and ablating LVAs.
Does voltage-guided ablation targeting low voltage areas improve outcomes in patients with atrial fibrillation?
Does voltage-guided ablation targeting low voltage areas improve outcomes in patients with atrial fibrillation?
While targeting low voltage areas in AF ablation shows theoretical promise, current evidence is mixed due to methodological heterogeneity and the complex nature of the atrial arrhythmogenic substrate.
Voltage-guided ablation should not yet alter AF strategies; leaves open the role of low-voltage targeting pending consistent trial data.
The prevalence of atrial fibrillation (AF) is forecasted to increase manifold, emphasizing the need for efficacious treatments. Pulmonary vein isolation (PVI) to eliminate ectopic triggers is now established as a fundamental component of the invasive treatment of AF, however its efficacy in persistent AF remains suboptimal. The atrial myocardium undergoes adverse fibrotic remodeling as AF progresses, favoring arrhythmia initiation and maintenance. Reductions in left atrial bipolar voltage have been suggested to identify regions of such pathological remodeling, and represent novel targets for ablation to target the arrhythmogenic substrate. Early observational studies targeting these low voltage areas (LVA) have been encouraging, however results from more recent randomized trials are more mixed. Importantly, there is significant heterogeneity in the techniques for identifying LVAs and the strategies for ablation. In reality, the atrial arrhythmogenic substrate is multi-faceted rather than being limited to fibrosis and there remains uncertainty as to how accurately LVAs represent regions of fibrosis. Additionally, bipolar voltage is influenced by numerous physiological and biophysical factors. The present review summarizes the current evidence for LVA ablation in AF. We then analyze the components of the atrial arrhythmic substrate, its relationship to LVAs and the limitations in LVA assessment. Finally we discuss novel techniques for delineating the atrial substrate.
No takes yet. Share an insight, caveat, or question.
Valli et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: